Gilead Sciences Inc (GILD: NAS):企業概要、財務分析、所属産業分析、競合他社との比較分析

◆英語タイトル:Gilead Sciences Inc (GILD: NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry
◆商品コード:PLUK41106012
◆発行会社(リサーチ会社):Plunkett Research
◆発行日:2014年10月28日
◆ページ数:73
◆レポート形式:English / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD1,795 ⇒換算¥201,040見積依頼/購入/質問フォーム
Multi User(社内共有可)USD4,795 ⇒換算¥537,040見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はPlunkett Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Plunkett Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Gilead Sciences Inc (GILD: NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry

Key Findings:
• Unique new report provides deep financial benchmarks for (Gilead Sciences Inc, GILD: NAS) compared to its top competitors and compared to the average for all companies within its primary industry.
• Benchmarking study for (Gilead Sciences Inc) includes growth forecast for its primary industry to the year 2021.

The purpose of this report is to provide vital corporate-specific benchmarks, comparing the Subject Company to its top competitors (on a company-by-company basis) and to the averages within its primary industry for all key metrics.

This is a unique report containing high-value data. The report begins with a superb overview of the primary industry of the Subject Company, including historical industry revenues, revenue forecasts and CAGR. Then the report moves into industry averages and metrics, then into data specific to the Subject Company, with comparative data for the Subject Company’s top competitors.

This report will save countless hours of research and analytical work for the end user.

Core Benefits to Customer:
1) Comprehensive benchmarks for the Subject Company:
a. Benchmarked against the leading firms in its primary industry
b. Benchmarked against the average for publicly-held companies (U.S.) in its industry.
c. This includes financial results, ratios, vital statistics and metrics in one package, including historical and current metrics and averages for 6 years within its primary industry.
2) A snapshot overview of the company’s primary industry, including current and historic revenues and employment, along with a long term forecast for industry growth, with CAGR (compound annual growth rate), employee population and much more.
3) Detailed rankings of the Subject Company against top companies within the industry (U.S.-based firms) for key items including:
a. Approximate market capitalization
b. Employees
c. Revenues
d. Net income
e. 3-Year revenue growth (%)
f. 3-Year income growth (%)
g. Return on assets (%)
h. Return on equity (%)
i. Return on invested capital (%)
4) Leading companies—profiles of the Subject Company as well as profiles of top competitors within the industry

Pages: 73
Statistical Tables Provided: 27
Charts Provided: 15
Geographic: US

This report is part of the Plunkett’s Corporate Benchmarks series, published by the Plunkett Analytics unit of Plunkett Research, Ltd. Plunkett Research has unique capabilities for creating corporate and industry information, due to the industry and company research that we have been conducting for more than 20 years. Our access to hundreds of industry tables from our own databases, along with our databases of public and private company information, industry trends analysis and other resources, have been utilized in preparing this report. Similar reports are available from for all significant, U.S. publicly-held firms.

Designed to benefit:
• Analysis and Financial Modeling
• Investment Professionals
• Lenders
• M&A Advisors
• Appraisers
• Consultants

“Plunkett Research has built a solid reputation providing industry analysis and research in a diverse spectrum of areas—energy and utilities, finance and investment, health care and biotechnology, and engineering and research to name a few.” American Reference Books Annual

Companies Profiled:
• Johnson & Johnson
• Pfizer Inc
• Merck & Co Inc
• Eli Lilly & Company
• Abbott Laboratories
• AbbVie, Inc.
• Amgen Inc
• Bristol-Myers Squibb Co
• Genentech Inc
• Gilead Sciences Inc

【レポートの目次】

I. Introduction
A. Core Benefits to Customer:
• Comprehensive financial performance benchmarking, including, in one package, the Subject Company’s
1) Financial results
2) Financial history
3) Ratios
4) Vital metrics
• Industry-specific comparative financial analysis and benchmarking of the Subject Company to:
1) Deep financials of each of the leading firms in the Subject Company’s primary industry
2) Detailed, multi-year financial averages for all companies within the industry
3) Rankings of the Subject Company against the top ten companies within the industry
• Profiles of the Subject Company and of its industry’s leading firms

II. Industry Analysis Summary of the Subject Company’s Primary Industry
• Industry revenues, employee count and growth rate for 2013
• Top U.S. companies, by revenues (table)
• Industry revenues, current and historical (chart)
• Industry employee population, current and historical (chart)
• Industry revenue yearly history and forecast from 2014 to 2021, with yearly CAGR

III. Industry Revenues, Historical and Projected
• Historical revenues and annual growth rates, 2006-2013
• Projected revenues & annual growth rates, 2014-2021

IV. Comparative Financial Benchmarks for the Subject Company by Industry Averages in a 6-year Time Series of Detailed Financials

A. Detailed table of companies used in computing these averages
B. Income statement averages, 2008-2013
• All income statement items, including cost of sales, SGA, R&D, salaries and wages, and EBITDA, with ratios
• Chart showing average company’s key expenses as a percent of revenues
C. Balance sheet averages, 2008-2013
• All items, including property plant and equipment; accumulated depreciation; goodwill; and long term debt, including ratios
D. Cash flow averages, 2008-2013
• All cash flow items

V. Competitive Summary of Top Companies Within the Industry, Profiles & Ranks
Profiles, financial reports, ranks & executive lists for up to 10 top U.S.-based corporations

A. Top companies within the industry ranked for key performance items
• Approximate market capitalization
• Employees
• Revenues
• Net income
• 3-Year revenue growth (%)
• 3-Year income growth (%)
• Return on assets (%)
• Return on equity (%)
• Return on invested capital (%)

B. Benchmarking of the Subject Company and its industry’s leading firms to each other and to their industry’s averages for all financial analysis metrics

• Income statements, balance sheets and cash flow statements for the Subject Company and for each of the top companies compared to each other and to the overall industry average

C. Corporate profiles, comparative analysis of the Subject Company and of the top companies within its industry, including executive listings and financial results

• Contact information, executive lists
• Business descriptions
• Key financial data for 6 years
• Brands and divisions
• Top salaries
• Corporate culture
• Charts comparing revenues vs. net income

VI. Data Description, Limited Warranty, Copyrights and Sources



【掲載企業】

• Johnson & Johnson
• Pfizer Inc
• Merck & Co Inc
• Eli Lilly & Company
• Abbott Laboratories
• AbbVie, Inc.
• Amgen Inc
• Bristol-Myers Squibb Co
• Genentech Inc
• Gilead Sciences Inc


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Gilead Sciences Inc (GILD: NAS):企業概要、財務分析、所属産業分析、競合他社との比較分析(Gilead Sciences Inc (GILD: NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆